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1. Introduction 
As our understanding of underlying mechanisms  evolve disease  definitions are adapted 
and refined. For example, until recently, one of the main distinctions between the definition 
of asthma and COPD was the presence or absence of reversible airflow obstruction. As 
greater advances are made in understanding  pathology, newer and better definitions 
encompass the overlap that exists between these two conditions and the recognition that 
chronic inflammation underlies both.  
Despite greater understanding of the inflammatory processes that drive asthma, there 
remains a lack of consensus regarding a definition and standards for diagnosis. Asthma is a 
clinical syndrome and currently there is no single test that confirms its presence. This has 
hampered studies of asthma epidemiology, as different investigators have used differing 
inclusion criteria to identify cases of disease.  
As well as identifying the presence of disease, there is a need to understand the natural history 
of asthma in order to identify which therapeutic interventions are most likely to be beneficial at 
any given time. A growing body of evidence suggests that although several current treatment 
strategies are effective in controlling symptoms, none change the natural course of the illness. It 
is, therefore, crucial to identify  risk factors for the development of asthma and triggers for 
asthma symptoms in order to develop effective primary and secondary prevention strategies. 
This chapter will discuss how asthma is diagnosed, its incidence and prevalence, the 
associated healthcare utilization, and morbidity and mortality. It will also outline the clinical 
phenotypes associated with the onset, remission and progression of asthma, over time.. 
2. Definitions 
Most definitions of asthma have emphasized the variable nature of symptoms, the presence 
of airflow obstruction and the reversible nature of the airflow obstruction, at least in the 
early stages of disease [1,2]. As the pathophysiology of asthma has become clearer, 
definitions have changed to include a statement of pathology. The latest definition to be 
widely embraced is a description of asthma as: 
“A chronic inflammatory disorder of the airways in which many cells and cellular elements play a 
role. The chronic inflammation is associated with airway hyper-responsiveness that leads to recurrent 
episodes of wheezing, breathlessness, chest tightness and coughing; particularly at night or in the 
early morning. These episodes are usually associated with widespread but variable airflow obstruction 
within the lung that is often reversible either spontaneously or with treatment” [1]. 
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In keeping with current theories, this definition implies that asthma is one disorder, rather 
than multiple complex disorders and syndromes [3] without detracting from its variable 
clinical presentation and course. This definition may encompass the spectrum of disease 
present and its inflammatory basis, but it is clinically unwieldy, as it does not provide a 
clear set of diagnostic criteria from which to identify patients. A more clinically relevant 
definition of asthma will not come into being until the pathogenesis of this condition is 
understood and a diagnostic biomarker is identified.  
3. An overview of inflammation 
Currently asthma is understood as being a chronic inflammatory disease where gene-
environment interactions (often with different sensitizing agents) lead to the release of 
inflammatory mediators, the recruitment of specific cell populations, and airflow 
obstruction. The airflow limitation may range from being completely reversible to being 
fixed. Historically, there has been difficulty differentiating between COPD and asthma. 
These conditions can co-exist, so the clinical picture can reflect both, which may complicate 
the diagnostic process and alter responses to treatment. However, while symptoms and the 
results of forced respiratory maneuvers can be similar, there is increasing recognition that 
there are differences in the pulmonary inflammatory profile of patients with asthma and 
COPD that can help to differentiate between the two conditions [4]. An overview of the 
inflammatory cascade in asthma and COPD is provided in figure 1. 
 
Fig. 1. A broad overview of pulmonary inflammation in asthma and COPD  
(adapted from [5]). 
stimulant 
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There are also differences in the pathology and immunology of mild to moderate and severe 
asthma, which can also complicate diagnosis. It is increasingly recognized that while mild 
and moderate asthma is a disease of eosinophils, severe asthma is associated with an influx 
of neutrophils[6]. It is hypothesized that that this difference in cell types may explain in part 
the increased resistance seen to corticosteroids with severe asthma, as neutrophilic 
inflammation is classically less responsive to this form of therapy [7]. It is unclear, however, 
whether neutrophils are causally related to severe asthma, or whether their presence is 
secondary to the frequent use of corticosteroids and unrelated to the natural history of the 
disease. Table 1 highlights differences in pulmonary inflammation in Asthma, Severe 
asthma and COPD. 
 
 ASTHMA SEVERE ASTHMA COPD 
Predominant Cells 
present in the lungs 
Eosinophils 
Macrophages 
CD4+ T Cells (TH2) 
Neutrophils 
Macrophages 
CD4+ T Cells (Th2) 
Neutrophils 
Macrophages 
CD8+ T Cells (Tc1) 
Key mediators in 
lung secretions and 
lung biopsies 
Eotaxins 
IL-4, IL-5, IL-13 
Nitric oxide 
IL-8, IL-5, IL-13 
Nitric Oxide 
IL-8, TNF-alpha, IL-1 
beta, LTB4, IL-6 
Site of Disease Proximal airways 
Proximal airways and 
peripheral airways 
Peripheral airways, 
lung parenchyma, 
pulmonary vessels 
Pathological 
features 
Fragile epithelium 
Mucous metaplasia 
Thickening of the 
basement membrane 
Oedema 
Bronchoconstriction 
Fragile epithelium 
Mucous metaplasia 
Thickening of the 
basement membrane 
Oedema 
Bronchoconstriction 
Squamous 
metaplasia, mucous 
metaplasia, small 
airway fibrosis, 
destruction of 
parenchyma. 
Response to 
treatment 
Large response to 
bronchodilators. Good 
response to steroids 
Smaller or no 
bronchodilator 
response and reduced 
response to steroids 
Small bronchodilator 
response, but this 
can alter with 
repeated testing, 
poor response to 
steroids 
Adapted from [5]. 
Table 1. Differences in pulmonary inflammation asthma, severe asthma and COPD.  
4. Severity classifications and asthma control 
International guidelines stratify asthma by severity, using symptoms, exacerbations and 
markers of airflow obstruction (FEV1 or peak expiratory flow). Severity classifications are 
Intermittent, Mild persistent, Moderate Persistent and Severe Persistent (table 2.)  These 
scoring systems were only meant to be applied to patients not receiving inhaled 
corticosteroids [5] since this therapy  can dramatically alter disease control. Despite this, it 
was widely recognized that this severity classification was often erroneously applied to 
www.intechopen.com
 
Bronchial Asthma – Emerging Therapeutic Strategies 
 
6 
patients already on treatment [8] and that the usefulness of such a system was limited. 
Severe Persistent asthma can become Mild or Intermittent Asthma if it is suitably controlled 
with medication, however, this change in severity classification may not reflect the severity 
of asthma present initially, nor the difficulty with which control was achieved [9]. Currently 
this classification system is limited to research studies only. 
In light of these factors there has been a move to classify the severity of asthma by its clinical 
expression - characterizing symptomatic control [10]. This provides clear targets for 
physicians and patients and an easily recognized trigger mechanism to increase or decrease 
therapeutic regimes. Table 3 describes how asthma control is currently characterized.  
 
 
Intermittent 
Symptoms less than once a week 
Nocturnal symptoms not more than twice a month 
Brief exacerbations 
FEV1 or PEF > 80% predicted 
FEV1 or PEF variability < 20% 
Mild 
Symptoms more than once a week but less than once a day 
Nocturnal symptoms more than twice a month 
Exacerbations may affect activity and sleep 
FEV1 or PEF > 80% predicted 
FEV1 or PEF variability < 20 - 30% 
Moderate Persistent 
Symptoms daily 
Nocturnal symptoms more than once a week 
Exacerbations may affect activity and sleep 
Daily use of short acting beta2 agonists 
FEV1 or PEF 60 - 80% predicted 
FEV1 or PEF variability > 30% 
Severe Persistent 
Symptoms daily 
Frequent nocturnal symptoms  
Frequent Exacerbations 
Limitations of physical activity 
FEV1 or PEF  < 60 % predicted 
FEV1 or PEF variability > 30% 
Adapted from [5]. 
Table 2. Asthma classification by severity before treatment 
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Characteristic 
Controlled 
(all of the following) 
Partly controlled (any 
measure present in 
any week) 
Uncontrolled 
Daytime symptoms 
None (twice or less a 
week) 
More than twice a 
week 
Three or more features 
of partly controlled 
asthma present in any 
week 
Limitations of activity None Any 
Nocturnal symptoms None Any 
Need for reliever/ 
rescue medication 
None (twice or less a 
week) 
More than twice a 
week 
Lung function  
(FEV1 or PEF) 
Normal 
< 80% predicted or 
personal best 
 
Exacerbations None One or more a year Once in any week 
Adapted from [5]. 
Table 3. Levels of asthma control 
All current international guidelines use asthma control to classify severity and to signal the 
need for a change in treatment strategy in a step-wise manner. However, many studies of the 
epidemiology and natural history of asthma still refer to severity in accordance with Table 2. 
5. Epidemiology 
Studies of asthma epidemiology have been hindered by the lack of  an agreed diagnostic 
standard. There is controversy as to whether symptoms and airway hyper-responsiveness 
should be assessed separately or jointly, although there is a poor correlation between the 
presence of symptoms and airway hyper-responsiveness [11,12].  
6. Incidence 
Incidence rates for asthma vary in accordance with the age of the population under study 
and the diagnostic criteria used. Global estimates suggest that there are at least 300 million 
people worldwide with asthma, with a predicted 100 million additional cases by 2025 [5,13]. 
Asthma incidence rates are highest in early childhood and in male children until puberty  
[14] and appear to be rising. A study in the USA described childhood asthma incidence rates 
to be 183 per 100,000 children in 1964 and 284 per 100,000 in 1983 [15]. The incidence of 
adult-onset asthma is highest in females (3 per 1000 person-years compared with 1.3 per 
1000 person-years in males) [16]  but these do not appear to be increasing [15]. 
7. Prevalence 
There have been many studies estimating the prevalence of asthma in differing 
communities. Overall, the global prevalence ranges from 1% to 18% of the population in 
different countries [17]. Data suggest that there are increases in prevalence of asthma in 
children and in older adults in developing countries and decreases in the prevalence of 
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asthma in the developed world [18]. Urbanisation appears to be a risk factor for asthma, as 
its prevalence has consistently been shown to be higher among children living in cities 
compared with those living outside urban developments [19,20]. Possible explanations for 
this include  atmospheric agents, the hygiene hypothesis where reduced exposure to 
allergens leads to a less tolerant immune response, a poorer socioeconomic background and 
differences in healthcare utilization. These remain as yet unproven. 
8. Healthcare utilization 
The global financial impact of asthma is substantial. Healthcare utilization accounts for the 
largest proportion of these costs and is increasing annually. In 2000, the estimated annual 
costs for asthma in the USA was $12.7 billion  (8.1 for direct costs, 2.6 related to morbidity, 
2.0 related to mortality). In 2007 this figure had risen to an estimated $50.1 billion [21]. On an 
individual basis, the direct health care costs associated with asthma in the USA  are 
approximately $3,300 per person with asthma each year [21].  
Increased hospital admissions  account for a significant proportion of the rising costs and 
have been documented worldwide, including in the UK, New Zealand, USA, and Australia 
[21-23]. A study comparing asthma hospitalisations in the 1960s and the 1980s reported a 
50% increase in cases of children with an exacerbation of asthma and a 200% increase in 
cases of adults across these decennials [24]. There has also been a significant rise in asthma-
related contact with a family physician [25].  
9. Morbidity and mortality    
Increased utilization of healthcare and monetary spend on asthma has not correlated with 
vast improvements in mortality or morbidity. The World Health Organisation estimates that 
15 million disability-adjusted life years (DALYS) are lost annually due to asthma [13,26]. 
This represents 1% of the total global disease burden. Annual worldwide deaths from 
asthma have been estimated at 250,000, but mortality does not correlate well with 
prevalence. Indeed, the countries that currently suffer the highest prevalence  (Northern 
America, UK, New Zealand) enjoy the lowest mortality rates [26]. In developed countries, 
death rates appear to be stable. In the USA  mortality has remained at approximately 3,500 
deaths per year for five years [21], while in the UK annual mortality rates have remained 
stable at approximately 1300 per annum [27].  
10. Demographics and asthma 
The epidemiology of asthma is associated with by age-related sex differences. Asthma and 
wheezing are more prevalent in young boys compared with young girls [14],  but this trend 
disappears during puberty [28]. In a study of 16 countries, it was reported that girls had a 
lower risk of developing asthma than did boys during childhood, this risk was equal at 
puberty, and reversed in young adults [29]. Women older than 20 years have both a higher 
prevalence and higher morbidity rates from asthma, and are more likely to present to 
hospital and be admitted for treatment [30,31]. They also have more severe disease and 
higher mortality rates [32] . The reason for this disparity is unclear but genetic and hormonal 
factors are likely to contribute. 
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As well as clear gender differences, there are also racial differences in the prevalence of 
asthma. In the USA, morbidity from asthma has been consistently shown to be greater in 
children of African American descent (for example, 13.4% of African American children and 
9.7% of white children [33]). Furthermore, children of African American descent are 
reported to have asthma which imposes a greater limitation on activity, with more hospital 
admissions but fewer family physician visits when compared to white children [34]. Data 
also suggest that asthma-associated mortality in children of  African American and Puerto 
Rican descent is higher than in any other group [35].  
Socioeconomic forces also appear to be important in asthma, and studies suggest that asthma 
severity is  increased in poorer communities [36] . This may reflect environmental factors such 
as exposure to smoke and occupational hazards, as well as health care utilization. 
11. The natural history of asthma    
Most models of chronic disease suggest there is a common natural history to all diseases, 
which begin with a prodromal stage, prior to disease presentation.  
This pre-illness period is defined as the period when subjects are free of overt disease but who 
have the susceptibility for the development of the condition (such as a genetic predisposition 
towards disease). During this phase, disease development is not inevitable and identifying 
individuals at risk provides an opportunity to prevent disease emergence. The disease 
manifests itself only after exposure to necessary environmental triggers (epigenetics). 
Following disease emergence, the condition can progress unabated (the natural course of the 
disease), or disease-modifying strategies can be employed to protect or reduce disease 
presentation, or to affect a cure. See figure 2 for a diagrammatic representation of this. 
 
Fig. 2. A hypothetical representation of the course of a chronic disease (adapted from [37]).  
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The prodromal stage equates to disease predisposition before the advent of triggers which 
cause disease manifestation. Following exposure, the disease presents, but this could 
theoretically be avoided if disease predisposition were known and exposure avoided. 
Following presentation, the disease can progress, or could be controlled or cured by 
appropriate management (treatment or exposure avoidance). Presently asthma is not curable 
using existing therapeutic strategies and while there is a need to expand treatment regimes, 
there is also great interest in identifying asthma susceptibility factors, which would allow 
patients to be diagnosed in the prodromal phase of asthma, before the advent of symptoms. 
This is likely to involve studies of genetic and environmental factors. 
12. The genetics of asthma 
There is great interest in understanding the natural course of asthma. Asthma is a 
heterogenous condition and there remains some controversy as to whether asthma is a single 
disease entity or whether it represents a common  label for a number of disease phenotypes. A 
disease phenotype represents a set of characteristics that are important in terms of disease 
progression or prognosis and it is increasingly apparent be that specific cohorts of asthma 
patients experience different presentations of disease and  warrant different treatment 
strategies. Specific disease phenotypes may also experience different prognoses. 
There are now numerous studies of the pattern of inheritance of asthma [38], rhinitis [39], 
allergic dermatitis [40], and serum IgE levels [41] and these have clearly shown that the 
familial concordance is partly due to shared genes. There are several loci that may be 
involved in the pathogenesis of allergy and asthma (see Table 4). In common with other 
complex diseases, independent investigators have not been able to reproduce many of these 
results. There are several explanations for this including genetic heterogeneity between 
populations, differences in phenotype definition, and lack of a consensus over the 
appropriate significance levels to use in these studies. A number of candidate linked have 
been repetitively associated with the presence of asthma or asthma severity and have a 
plausible biological role in the development of the disease.  
 
Candidate Genes 
Interleukin 4    B2 adrenergic receptor 
Tumour Necrosis Factor ┙   Intereukin -4 receptor a 
HLA,     N-Acetyltransferase 
┙1-antitrypsin    Angiotensin-converting enzyme 
Interleukins 5, 9, and 13,    Glucocorticoid receptor,  
CD14      Clara cell protein 16,  
Transporter antigen peptide 1,  Interleukin 9 receptor,  
Immunoglobulin heavy chain genes,  T cell antigen receptor ,  
T cell antigen receptor    
┚ Subunit of the high-affinity IgE receptor 
 
Table 4. Candidate Genes in Allergy and Asthma 
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On chromosome 6p21, there is an important region that contains the genes for the major 
histocompatibility (MHC) molecules as well as the tumor necrosis factor ┙ (TNF-┙) and 
lymphotoxin genes. This area of chromosome 6 has been repeatedly identified in linkage 
and association studies. Most of the data concerns the association of specific MHC genotypes 
with sensitization to specific aeroallergens [42]. On chromosome 5q there are many 
candidate genes for asthma and allergy such as the interleukin 4 and ┚2-adrenergic receptor 
genes both of which have been associated with asthma  [43] . Chromosome 11q13 has been 
linked to a variety of different phenotypes and the ┚ chain of the high-affinity IgE receptor 
has been proposed as a candidate for this linkage [44]. The region containing the interleukin 
4 receptor  ┙ chain (16p12) has also been implicated in IgE responsiveness [45]. 
It is hypothesized that polymorphisms within these candidate gene alter pro-inflammatory 
protein expression and cellular functions to cause a predisposition towards asthma or 
alterations in responses to treatment (especially in the case of ┚2 adrenergic and 
glucocorticoid receptors). In most cases the functional consequences of genetic variation 
have not been assessed, and these remain associations only, but there is great interest  in 
characterizing predispositions further in order to modify risk. 
13. Asthma phenotypes and progression 
There have been longitudinal studies that have addressed how asthma progresses and these 
have begun to explore the effect of disease phenotype on outcome [46-48].  
14. Asthma phenotypes with age  
14.1 Early childhood  
Longitudinal studies have consistently confirmed that most cases of chronic, persistent 
asthma start in early childhood, with the initial presentation occurring during the first 5 
years of life [15,46,48]. There are some methodological concerns with these studies, as most 
ask parents to document or recall recurrent symptoms of wheeze or cough. These can 
represent recurrent viral infections and only a small proportion of these children will go on 
to develop persistent asthma [49], however the association between childhood symptoms 
and persistent asthma later in life appears robust.  
Further work has tried to understand which children are most at risk of developing asthma. 
The vast majority of infants who become wheezy during infections do not go on to develop 
asthma. Most of these infants (representing two thirds of cases of wheeze) have one or two 
episodes of wheeze before the age of two, but these do not recur after this age and this 
presentation is termed “Transient wheezing of infancy” [50]. Studies suggest that the most 
important risk factors for transient wheezing in infancy are exposure to respiratory viruses 
(especially RSV) [49], maternal smoking in pregnancy and lower lung function values 
[51,52]. Remission is thought to occur due to growth of the airways and lung parenchyma 
[53] but currently there is no evidence that any particular active intervention reduces 
progression to asthma although bronchodilators improve both symptoms and lung function 
measurements, suggesting disease is related to bronchomotor tone. Sensitisation to 
aeroallergens is associated with a risk of chronic asthma in later life, but interestingly, 
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symptoms seem to start 2 – 3 years later than in those whose asthma is not associated with 
atopy [54]. Furthermore, treating this sensitization is associated with a reduction in the 
development of asthma [55]. 
14.2 Adolescent to adulthood 
Birth cohort studies suggest that over 60% of children who are frequently wheezy or who 
have a physician diagnosis of asthma go on to experience asthma-like symptoms as an 
adolescent [56]. Chronic asthma symptoms that persistent into adolescence and early 
adulthood are associated with both sensitization to allergens and elevated levels of 
circulating IgE [57]. Different allergens appear important in different geographical regions, 
for example in desert regions the mould Alternaria is associated with asthma [58], while in 
more temperate and coastal regions, house dust mite is the more likely relevant sensitizing 
agent [59]. The ability to detect the allergen most closely associated with disease varies 
according to region, and there are likely to be more unidentified allergens that are 
associated with disease.  
Identifying the exact allergen responsible in each patient may be less important than 
characterizing the inflammatory reaction present. The key features of asthma including 
symptoms, disordered airway function, airway inflammation, exacerbations and the decline 
in lung function, are not closely related to each other within patients and might have 
different drivers. There is no clear causal link between eosinophilic airway inflammation 
and airway hyper-responsiveness [60] and infiltration of airway smooth muscle by mast 
cells may be more relevant [61]. In contrast, asthma exacerbations are more closely related to 
eosinophilic airway inflammation[60]  
15. Asthma remission or progression 
Large, long term population based prospective studies have tried to identify factors that 
predict who will progress and experience persistent, severe asthma, and who will remit  
[62-64].  
In all studies, severity and frequency of symptoms in early childhood predict outcomes in 
adulthood. Those that experience mild and infrequent symptoms in early life go on to 
experience no or mild asthma-related symptoms. Those with the most severe symptoms 
have persistent severe asthma in later life. In one population based study, 52% of children 
(aged 10) with asthma and 72% of children with severe asthma had frequent or persistent 
wheeze age 42 [65].  
The majority of patients with persistent asthma in later life demonstrated evidence of an 
allergic predisposition (with allergic rhinitis or eczema in childhood) [47]. 
Deficits in lung volumes during childhood are also consistently associated with persistent 
asthma in adulthood [65]. The presence of abnormal lung function in childhood is a 
predictor of asthma and children who wheeze or who have a diagnosis of asthma, who then 
go on to have persistent asthma in adulthood have reductions in FEV1 and FEV1/ FVC ratio 
compared with controls throughout life. Interestingly, the slope of decline over time does 
not alter between wheezers and controls in this group [47],  suggesting that developmental 
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factors are important in asthma sustainment in this group, but that these factors do not 
contribute to accelerated decline in lung function in later life.  
In contrast  to this, when asthma symptoms occur in later life (aged over 25 years), they are  
associated both with moderate deficits in FEV1 and FEV1/FVC in early adulthood and a 
faster decline in lung function in subsequent years [53]. This, combined with studies of 
inflammation [66], suggest that in this group, developmental factors combined with 
epigenetic influences such as inflammatory polymorphisms or environmental stimuli, lead 
to progressive disease. Airway hyper-responsiveness appears to be an important component 
of this, and has been consistently associated with progression to adult asthma in a number 
of studies [47,56]. 
Less is known about factors that cause the re-emergence of asthma following a period of 
remission in early adulthood. There is evidence that remission may be a clinical phenomena 
rather than a true abatement of disease, as it is not associated with a loss of inflammation or 
bronchial hyper-responsiveness. Indeed, eosinophil counts, exhaled nitric oxide and 
concentrations of IL-5 remain higher in asthma patients with no symptoms who are off 
treatment than sex and age-matched controls [67]. It might be that environmental and 
genetic factors combine in these patients so that their burden of inflammation crosses a 
symptomatic threshold, leading to disease re-emergence, but there are no studies that 
explore this hypothesis.  
16. Conclusion 
Asthma is a common, chronic inflammatory lung condition associated with variable airflow 
obstruction and symptoms of breathlessness, cough and wheeze. Age of onset, severity and 
clinical course varies between patient groups, and these clinical phenotypes are likely to 
reflect differences in the genetic, developmental and environmental factors which 
predispose to disease and trigger symptoms. Currently, these factors are not well 
understood, but they are likely to be vital in determining which patients go on to experience 
worsening disease outcomes and which patients respond to certain treatment regimes.  
The continued presence of inflammation even in quiescent disease suggests that current 
treatment strategies are not treating the drivers of disease, but instead are modifying 
disease-related symptoms by transiently reducing inflammation. As effective as current 
treatments are for the majority of patients, more research is needed to determine the causes 
of asthma in different patient populations. 
Understanding the epigenetics of asthma will allow for new treatment strategies,  where 
specific medications are targeted to specific cohorts of patients based upon their 
inflammatory make-up and disease presentation.  
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